Pre-treatment screening for DPD deficiency is the key for 5-FU-based therapy

5-Fluorouracil (5-FU) is a fundamental part of chemotherapy for malignant tumors. Although it is  considered to be a generally safe and effective chemotherapeutics, 5-FU has shown serious side effects up to 30%. A single enzyme, dihydropyrimidinedehydrogenase (DPD), is responsible for the degradation of 80% of 5-FU to inactive metabolites which is mediated through hepatic metabolism. A mutation in the DPYD gene can cause DPD deficiency, causing less or no degradation of  5-FU. While heterozygous patients should be given lower 5-FU doses, homozygous patients should receive alternative chemotherapeutic treatment. To this date, pre-treatment screening for DPD deficiency in patients with plannend 5-FU-based therapy is not standard treatment.

Goffin Molecular Technologies offers the PGX-5FU StripAssay ® from ViennaLab. This test can identify the SNP of the DPYD allelic variant IVS14+1 G>A that is associated with toxicity of 5-FU therapy.

More information about the PGX-5FU StripAssay ® can be found in the brochure and the manual.

Complimentary product: The cancer StripAssays from ViennaLab cannot only detect mutations of the DPYD gene but also mutations such as BRAF, KRAS and NRAS. Click here to find out more!

Share on facebook
Share on email
Share on linkedin

Copyright © 2020 Goffin Molecular Technologies